Unit:
Κατεύθυνση Σακχαρώδης Διαβήτης και ΠαχυσαρκίαLibrary of the School of Health Sciences
Author:
Grammatikakis Apostolos
Supervisors info:
Νικόλαος Κ. Τεντολούρης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Μακρυλάκης Κωνσταντίνος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κόκκινος Αλέξανδρος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
SGLT2 αναστολείς και νεφροπροστασία
Translated title:
SGLT2 inhibitors and kidney protection
Summary:
One out of two patients with type 2 diabetes develop a certain degree of renal impairment and in many of them chronic kidney disease progresses to end-stage renal disease with increased risk of cardiovascular mortality. Although, renin-angiotensin system blockers are usually be used, a substantial residual risk of renal progression remains. The SGLT2 protein reabsorbs glucose and sodium in the kidney. The inhibitors of SGLT2 were firstly designed and developed for their hypoglycemic effect, but surprisingly reported a statistical significant reduction of overall mortality, cardiovascular risk and renal progression. The role of SGLT2i in the reduction of cardiovascular mortality and the preservation of the estimated glomerular filtration rate has been reported in many randomized controlled trials. The renal effects are pleiotropic and consist of direct and indirect effects. The SGLT2i have become important treatment target for the diabetic nephropathy. Recently, the beneficial role of SGLT2 have expanded in patients without diabetes. This review outlines the mechanisms, whereby the SGLT2s promote the renal effects, as well as the renal outcomes from the most important randomized trials in patients with or without diabetes.
Main subject category:
Health Sciences
Keywords:
SGLT2 Inhibitors, Renal protection, Diabetic nephropathy, Chronic kidney disease, Review
Number of references:
103
